TP53BP1 and cancer: Previously, Canny et al. discovered that inhibition of 53BP1 through an engineered ubiquitin variant called “i53”, delivered by either plasmid transfection or AAV, increased the frequency of Cas9-mediated HDR in human cancer cell lines20.